NEW YORK (TheStreet) -- Shares of MedAssets (MDAS) were falling 13.1% to $17.23 Wednesday on heavy trading volume after the healthcare performance improvement company guided below analysts' estimates for earnings for full year 2015.

MedAssets expects to report earnings of $1.13 to $1.23 a share for the full year 2015, below analysts' estimates of $1.45 a share for the year. The company expects revenue of $753 million to $767 million for 2015, compared to analysts' estimates of $758 million for the year.

The company reported earnings of 39 cents a share for the fourth quarter of 2014, in line with analysts' estimates. Revenue grew 16.3% year over year to $198.24 million, above analysts' estimates of $195.3 million.

Exclusive Report:Jim Cramer's Best Stocks for 2015

About 1.7 million shares of MedAssets were traded by 11:05 a.m. Wednesday, above the average trading volume of about 400,000 shares a day.

TheStreet Ratings team rates MEDASSETS INC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate MEDASSETS INC (MDAS) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

You can view the full analysis from the report here: MDAS Ratings Report

MDAS data by YCharts

Image placeholder title